Corticosteroids as adjunctive therapy in the treatment of influenza

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Rodrigo, Chamira ^a   Leonardi Bee, Jo ^b   Nguyen Van Tam, Jonathan ^c   Lim, Wei Shen ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE;

ARTIFICIAL VENTILATION; CORTICOSTEROID THERAPY; DRUG EFFICACY; EMBASE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; INFLUENZA; INFLUENZA A VIRUS (H1N1); INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG LAVAGE; MEDLINE; MORTALITY; NONHUMAN; PANDEMIC INFLUENZA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEASONAL INFLUENZA; SYSTEMATIC REVIEW; WEB OF SCIENCE; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CROSS INFECTION; INFLUENZA, HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; STATISTICS AND NUMERICAL DATA;

ADRENAL CORTEX HORMONES; CHEMOTHERAPY, ADJUVANT; CROSS INFECTION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84961895903     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010406.pub2     Document Type: Review

References (97)

1. Balaganesakumar SR, Murhekar MV, Swamy KK, Kumar MR, Manickam P, Pandian P. Risk factors associated with death among influenza A (H1N1) patients, Tamil Nadu, India, 2010. Journal of Postgraduate Medicine 2013;59:9-14.
2. Boudreault A, Xie H, Leisenring W, Englund J, Corey L, Boeckh M. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biology of Blood and Marrow Transplantation 2011;17(7):979-86.
3. Brun-Buisson C, Jean-Christophe M, Mercat A, Thiebaut A, Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 2011;183(9):1200-6.
4. Chawla R, Kansal S, Chauhan M, Jain A, Jibhkate B. Predictors of mortality and length of stay in hospitalized cases of 2009 influenza A (H1N1): experiences of a tertiary care center. Indian Journal of Critical Care Medicine 2013;17:275-82.
5. Delgado-Rodriguez M, Castilla J, Godoy P, Martin V, Soldevila N, Alonso J, et al. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. Journal of Antimicrobial Chemotherapy 2012;67(7):1739-45.
6. Diaz E, Martin-Loeches I, Canadell L, Vidaur L, Suarez D, Socias L, et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. Journal of Infection 2012;64(3):311-8.
7. Han K, Ma H, An X, Su Y, Chen J, Lian Z, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clinical Infectious Diseases 2011;53(4):326-33.
8. Jain S, Kamimoto L, Bramley A, Schmitz A, Benoit S, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. New England Journal of Medicine 2009;361(20):1935-44.
9. Kim S, Hong S, Yun S, Choi W, Ahn J, Lee Y, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. American Journal of Respiratory and Critical Care Medicine 2011;183(9):1207-14.
10. Kudo K, Takasaki J, Manabe T, Uryu H, Yamada R, Kuroda E, et al. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A (H1N1) pdm09 in Japan. PloS One 2012;7(2):e32280.
11. Li F, Chen G, Wang J, Liu H, Wu J. A case-control study on risk factors associated with death in pregnant women with severe pandemic H1N1 infection. BMJ Open 2012;2:e000827.
12. Liem N, Tung C, Hien N, Hien T, Chau N, Long H, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clinical Infectious Diseases 2009;48(12):1639-46.
13. Linko R, Pettila V, Ruokonen E, Varpula T, Karlsson S, Tenhunen J, et al. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A (H1N1) infection in Finland. Acta Anaesthesiologica Scandinavica 2011;55(8):971-9.
14. Mady A, Ramadan O, Yousef A, Mandourah Y, Amr A, Kherallah M. Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia. Journal of Infection and Public Health 2012;5(1):52-6.
15. Patel K, Patel A, Mehta P, Amin R, Patel K, Chuhan P, et al. Clinical outcome of novel H1N1 (swine flu)-infected patients during 2009 pandemic at tertiary referral hospital in western India. Journal of Global Infectious Diseases 2013;5:93-7.
16. Sertogullarindan B, Ozbay B, Gunini H, Sunnetcioglu A, Arisoy A, Bilgin HM, et al. Clinical and prognostic features of patients with pandemic 2009 influenza a (H1N1) virus in the intensive care unit. African Health Sciences 2011;11(2):163-70.
17. Viasus D, Pano-Pardo J, Cordero E, Campins A, Lopez-Medrano F, Villoslada A, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. Journal of Infection 2011;62(3):193-9.
18. Wu U, Wang J, Ho Y, Pan S, Chen Y, Chang S. Factors associated with development of complications among adults with influenza: a 3-year prospective analysis. Journal of the Formosan Medical Association 2012;111(7):364-9.
19. Xi X, Xu Y, Jiang L, Li A, Duan J, Du B, et al. Hospitalized adult patients with 2009 influenza A (H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infectious Diseases 2010;10:256.
20. Chan W, Chang K, Loung P, Lai C, Tse W. Serious pandemic influenza A/H1N1 infection in paediatric intensive care unit from 2009-2014. Hong Kong Journal of Paediatrics 2014;19:199-200.
21. Fujikura Y, Kawano S, Kouzaki Y, Shinoda M, Hara Y, Shinkai M, et al. The (H1N1) 2009 pandemic influenza pneumonia among adult patients in Japan. Japanese Journal of Infectious Diseases 2014;67:100-4.
22. Gao H, Lu H, Cao B, Du B, Shang H, Gan J, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. New England Journal of Medicine 2013;368:2277-85.
23. Garnacho-Montero J, Gutierrez-Pizarraya A, Marquez J, Zaragoza R, Granada R, Ruiz-Santana Sergio, et al. Epidemiology, clinical features, and prognosis of elderly adults with severe forms of influenza A (H1N1). Journal of the American Geriatrics Society 2013;61:350-6.
24. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013;381:2273-9.
25. Martin-Loeches I, Bermejo-Martin J, Valles J, Granada R, Vidaur L, Vergara-Serrano J, et al. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Medicine 2013;39:693-702.
26. McKenna J, Bramley A, Skarbinski J, Fry A, Finelli L, Jain S. Asthma in patients hospitalized with pandemic influenza A (H1N1) pdm09 virus infection - United States, 2009. BMC Infectious Diseases 2013;13:1-8.
27. Ning J. Diagnosis and treatment of children with severe influenza A from the 2009/2010 pandemic in Tianjin, China. Tropical Doctor 2014;44:69-70.
28. Okur M, Erbey F, Yazicioglu O, Celik A, Tukenmez B, Sunnetcioglu M. H1N1 influenza A virus related pneumonia and respiratory failure. Indian Journal of Virology 2013;24:85-9.
29. Smud A, Nagel C, Madsen E, Rial M, Barcan L, Gomez A, et al. Pandemic influenza a/H1N1 virus infection in solid organ transplant recipients: a multicenter study. Transplantation 2010;90:400.
30. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):862-71. [PUBMED: 12186604]
31. Annane D, Bellissant E, Bollaert P, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004;329:480. [DOI: 10.1136/bmj.38181.482222.55]
32. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301(22):2362-75. [DOI: 10.1001/jama.2009.815]
33. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ (Clinical research ed.) 2004;328(7454):1490. [PUBMED: 15205295]
34. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015;385:1511-8.
35. Bos WJW. Santeon-CAP; dexamethasone in community-acquired pneumonia. http://clinicaltrials.gov/show/NCT01743755A 2012 (accessed 22 July 2014).
36. Bridges L. Extended steroid in CAP(e) (ESCAPe). http://clinicaltrials.gov/show/NCT01283009 2011 (accessed 21 July 2014).
37. Brouwer MC, McIntyre P, de Gans J, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD004405.pub3]
38. British Thoracic Society. British guideline on the management of asthma. Thorax 2008;63(Suppl 4):iv1-121.
39. Chen Y, Li K, Pu H, Wu T. Corticosteroids for pneumonia. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007720.pub2]
40. Choi Su-Mi, Boudreault A, Xie H, Englund J, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 2011;117(19):5050-6.
41. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Molecular and Cellular Endocrinology 2011;335(1):2-13.
42. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. Journal of Infection 2014;68(4):363-71. [PUBMED: 24291062]
43. Dawood F, Iuliano A, Reed C, Meltzer M, Shay D, Cheng Po-Yung. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infectious Diseases 2012;12(9):687-95.
44. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, Chau TNB, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nature Medicine 2006;12(10):1203-7.
45. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine 2013;41(2):580-637.
46. Deyde V, Xu X, Bright R, Shaw M, Smith C, Zhang Y. Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide. Journal of Infectious Diseases 2007;196(2):249-57.
47. Donaldson LJ, Rutter PD, Ellis BM, Greaves FEC, Mytton OT, Pebody RG, et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2010;339:b5213. [DOI: 10.1136/bmj.b5213]
48. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD004878.pub4]
49. Giannella M, Alonso M, Garcia de V, Lopez Roa P, Catalan P, Padilla B, et al. Prolonged viral shedding in pandemic influenza A (H1N1): clinical significance and viral load analysis in hospitalized patients. Clinical Microbiology & Infection 2011;17(8):1160-5.
50. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
51. GRADEpro GDT. GRADEpro Guideline Development Tool (www.guidelinedevelopment.org). Hamilton: McMaster University (developed by Evidence Prime, Inc), 2015.
52. Heltzer ML, Coffin SE, Maurer K, Bagashev A, Zhang Z, Orange JS, et al. Immune dysregulation in severe influenza. Journal of Leukocyte Biology 2009;85:1036-43.
53. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. Jaattela M, Ilvesmaki V, Voutilainen R, Stenman UH, Saksela E. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 1991;128(1):623-9.
55. Jefferson T, Jones M, Doshi P, Del Mar C, Heneghan C, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD008965.pub4]
56. Kaiser L, Scott Fritz R, Straus S, Gubareva L, Hayden F. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. Journal of Medical Virology 2001;64:262-8.
57. Kaufmann, Briegel J, Schliephake F, Hoelzl AC, Alexander H, Theresia S, et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Medicine 2008;34(2):344-9.
58. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009;302:1872-9.
59. Lee N, Chan P, Hui D, Rainer T, Wong E, Choi KW, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. Journal of Infectious Diseases 2009;200:492-500.
60. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
61. Liu DH, Su YP, Zhang W, Lu SF, Ran XZ, Gao JS, et al. Changes in glucocorticoid and mineralocorticoid receptors of liver and kidney cytosols after pathologic stress and its regulation in rats. Critical Care Medicine 2002;30(3):623-7.
62. Marik PE. Critical illness-related corticosteroid insufficiency. Chest 2009;135(1):181-93.
63. Martin-Loeches I, Lisboa T, Rhodes A, Moreno RP, Silva E, Sprung C, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1) influenza A infection. Intensive Care Medicine 2010;37(2):272-83. [DOI: 10.1007/s00134-010-2078-z]
64. Molenaar N, Bijkerk RM, Beishuizen A, Hempen CM, de Jong MF, Vermes I, et al. Steroidogenesis in the adrenal dysfunction of critical illness: impact of etomidate. Critical Care 2012;16(4):1-9.
65. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A (H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. Journal of Infectious Diseases 2013;207(4):553-63.
66. Myles P, Nguyen-Van-Tam JS, Semple MG, Brett SJ, Bannister B, Read R, et al. Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. European Respiratory Journal 2013;41(4):824-31.
67. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 2014 (accessed June 2015).
68. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, Semple MG, et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 2010;65(7):645-51. [PUBMED: 20627925]
69. National Institute for Health and Care Excellence. Management of chronic obstructive pulmonary disease in adults in primary and secondary care. http://guidance.nice.org.uk/CG101 2010 (accessed June 2015).
70. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PloS One 2012;7:e47926.
71. Ortiz JR, Rudd KE, Clark DV, Jacob S, West TE. Clinical research during a public health emergency: a systematic review of severe pandemic influenza management. Critical Care Medicine 2013;41(5):1345-52.
72. Ortiz JR, Neuzil KM, Shay DK, Rue TC, Neradilek MB, Zhou H, et al. The burden of influenza-associated critical illness hospitalizations. Critical Care Medicine 2014;42(11):2325-32. [PUBMED: 25148596]
73. Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI, Widdowson MA. Influenza cost and cost-effectiveness studies globally - a review. Vaccine 2013;31(46):5339-48. [PUBMED: 24055351]
74. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD002244.pub3]
75. Quispe-Laime A, Bracco J, Barberio P, Campagne C, Rolfo V, Umberger R, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Medicine 2010;36(1):33-41.
76. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
77. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. New England Journal of Medicine 2005;353(16):1711-23.
78. Richard J, Pham T, Brun-Buisson C, Reignier J, Mercat A, Beduneau G. Interest of a simple on-line screening registry for measuring ICU burden related to an influenza pandemic. Critical Care 2012;16(4):1-10.
79. Russell KF, Liang Y, O'Gorman K, Johnson DW, Klassen TP. Glucocorticoids for croup. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD001955.pub3]
80. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340(c332):698-702. [DOI: http://dx.doi.org/10.1136/bmj.c332]
81. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Annals of Internal Medicine 2015;163(7):519-28. [PUBMED: 26258555]
82. Scottish Intercollegiate Guidelines Network (SIGN). Search filters, methodology. Available from http://www.sign.ac.uk/methodology/filters.html#obs 2011 (accessed 31 January 2012).
83. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Medicine 2013;10:e1001558.
84. Taubenberger J, Morens D. The pathology of influenza virus infections. Annual Review of Pathology: Mechanisms of Disease 2008;3(1):499-522.
85. To K, Hung I, Li I, Lee K, Koo C, Yan W, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clinical Infectious Diseases 2010;50(6):850-9.
86. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313(7):677-86.
87. Venekamp RP, Thompson MJ, Hayward G, Heneghan CJ, Del Mar CB, Perera R, et al. Systemic corticosteroids for acute sinusitis. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD008115.pub3]
88. Venkatesh B, Myburgh J, Finfer S, Webb SA, Cohen J, Bellomo R, et al. The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock. Critical Care and Resuscitation 2013;15(2):83-8.
89. Viboud C, Alonso WJ, Simonsen L. Influenza in tropical regions. PLoS Medicine 2006;3(4):e89.
90. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. PLoS Currents 2010;2:RRN1153. [DOI: 10.1371/currents.RRN1153]
91. Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Medicine 2012;38:1761-8.
92. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. New England Journal of Medicine 2005;353(13):1374-85.
93. World Health Organization. Influenza. http://www.who.int/immunization/topics/influenza/en/index.html 2008 (accessed August 2012).
94. World Health Organization. WHO guidelines for the pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf?ua=1 2010 (accessed June 2015).
95. Yu X, Zhang X, Zhao B, Wang J, Zhu Z, Teng Z, et al. Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6. PloS One 2011;6(12):e28680. [DOI: 10.1371/journal.pone.0028680]
96. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clinical Infectious Diseases 2012;54(10):1427-36. [PUBMED: 22495079]
97. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD010406]